Andrew received his B.Sc. from the University of Sunderland, UK and his Ph.D. from the University of Newcastle upon Tyne, UK. His research initially focused on genetic determinants of dementia, in particular Alzheimer’s disease and dementia with Lewy bodies. His postdoctoral studies were spent at the Mayo Clinic in Jacksonville Florida. Andrew moved to the National Institute on Aging at NIH Bethesda, MD in 2001 and became a principal investigator leading the Molecular Genetics Unit in 2002. In 2007 Dr Singleton became a tenured senior investigator at the National Institute on Aging, in 2008 he became the Chief of the Laboratory of Neurogenetics, and in 2016 he was named an NIH Distinguished Investigator.
Andrew has published more than 600 articles on a wide variety of topics. His laboratory comprises ~60 staff, including six principal investigators and three group leaders. His laboratory works on the genetic basis of neurological disorders including Parkinson's disease, Alzheimer’s disease, dystonia, ataxia, dementia with Lewy bodies, and amyotrophic lateral sclerosis. The goal of this research is to identify genetic variability that causes or contributes to disease and to use this knowledge to understand the molecular processes underlying disease. Most recently his work has expanded to the use of multimodal data in predicting disease.
Description of webinar:
In this talk, Dr Singleton will discuss the progress made so far in understanding the genetic basis of Parkinson’s disease. He will cover the history of discovery from the first identification of disease causing mutations to the state of knowledge in the field today, more that 20 years after that initial discovery. He will then discuss current initiatives and the promise of these for informing the understanding and treatment of Parkinson’s disease. Lastly, Dr Singleton will talk about current gaps in research and knowledge and working together to fill these.